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Abstract 
Background: The vast majority of cervical cancers are caused by high-risk strains of human 
papillomavirus (HPV). Conventional screening by Papanicolaou (Pap) smear can effectively prevent the 
development of cervical cancer, but transmasculine (TM) individuals (those assigned female at birth, but 
who do not identify as female) utilize screening less frequently than their cisgender counterparts. Self-
collected HPV samples may be viewed as more acceptable by TM patients and may be an equally 
effective screening method, which could ultimately increase cervical cancer screening uptake in this 
underserved population. 
Methods: An exhaustive search of the literature using MEDLINE-PubMed, CINAHL, and Web of Science 
with the terms transmasculine, screening, self, and HPV. The resulting studies were appraised and 
assessed for quality using GRADE. 
Results: Three studies met eligibility criteria and were included in this review. One observational study 
surveyed 91 transmasculine subjects and found that over 50% preferred self-collection methods for 
cervical cancer screening. An additional observational study collected information from 62 TM 
participants and found that a clear majority preferred self-collected frontal swabs, or at least provider-
collected frontal swabs, over traditional Pap testing. The final article described a mixed methods study, 
including both an observational and RCT portion. The authors found that most of the participants 
expressed similar preferences to those in the previous two studies. They also found substantial 
concordance between self-collected vaginal swabs and provider-collected cervical swabs, which is the 
current gold standard. 
Conclusion: Self-collected vaginal HPV samples are seen as highly acceptable among TM patients, show 
substantial concordance with Pap testing, and appear to be an efficacious alternative. This is especially 
true in patients who refuse conventional screening or are not utilizing preventative care. Offering self-
collection as a primary HPV screening method would likely increase cervical cancer screening uptake 
among the TM population. 
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Abstract 
Background: The vast majority of cervical cancers are caused by high-risk 
strains of human papillomavirus (HPV). Conventional screening by Papanicolaou 
(Pap) smear can effectively prevent the development of cervical cancer, but 
transmasculine (TM) individuals (those assigned female at birth, but who do not 
identify as female) utilize screening less frequently than their cisgender 
counterparts. Self-collected HPV samples may be viewed as more acceptable by 
TM patients and may be an equally effective screening method, which could 
ultimately increase cervical cancer screening uptake in this underserved 
population. 
Methods: An exhaustive search of the literature using MEDLINE-PubMed, 
CINAHL, and Web of Science with the terms transmasculine, screening, self, and 
HPV. The resulting studies were appraised and assessed for quality using 
GRADE. 
Results: Three studies met eligibility criteria and were included in this review. 
One observational study surveyed 91 transmasculine subjects and found that over 
50% preferred self-collection methods for cervical cancer screening. An 
additional observational study collected information from 62 TM participants 
and found that a clear majority preferred self-collected frontal swabs, or at least 
provider-collected frontal swabs, over traditional Pap testing. The final article 
described a mixed methods study, including both an observational and RCT 
portion. The authors found that most of the participants expressed similar 
preferences to those in the previous two studies. They also found substantial 
concordance between self-collected vaginal swabs and provider-collected cervical 
swabs, which is the current gold standard. 
Conclusion: Self-collected vaginal HPV samples are seen as highly acceptable 
among TM patients, show substantial concordance with Pap testing, and appear 
to be an efficacious alternative. This is especially true in patients who refuse 
conventional screening or are not utilizing preventative care. Offering self-
collection as a primary HPV screening method would likely increase cervical 
cancer screening uptake among the TM population. 
Keywords: Transmasculine, screening, self-collected, HPV, cervical cancer, 
perceptions, acceptability, efficacy, concordance 
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Efficacy and Acceptability of Self-Collected Versus 
Provider-Collected HPV Samples Among the 
Transmasculine Population 
BACKGROUND 
In the United States, human papillomavirus (HPV) is the most common 
sexually transmitted infection, and it is estimated that 1 in 4 people carry the 
virus.1 High-risk strains of HPV (hrHPV), namely 16 and 18, cause roughly 99% 
of all cervical cancer cases, which leads to substantial morbidity and mortality 
worldwide.1,2 Appropriate screening can detect hrHPV and cervical dysplasia, and 
ultimately prevent the development of cervical cancer through prompt treatment. 
The incidence of cervical cancer, and resultant death rate, declined by 
approximately 70% over the last 65 years, which is commonly attributed to 
regular screening through the Papanicolaou (Pap) test.1,3 In fact, most cases of 
cervical cancer occur in patients whom never had a Pap or have not had one in 
the last five years.1 This underutilization often happens in minority populations, 
including the gender diverse community. Studies4–6 suggest that TM patients are 
significantly less likely to be up to date on cervical cancer screening compared to 
cisgender women.  
Transmasculine (TM) patients were assigned female at birth, but identify 
along the masculine gender spectrum (man, trans man, non-binary, genderqueer, 
other). These patients still require cervical cancer screening unless the cervix has 
been surgically removed, which is usually not included in the procedure.7 TM 
patients face numerous physical, emotional, and logistical barriers to cervical 
cancer screening. The speculum exam required to obtain a cytology sample is 
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invasive and often heightens feelings of gender dysphoria as patients are forced 
to face the discordance between self-perception and genital anatomy.7–9 Many 
patients report previous trauma surrounding pelvic examinations and for those 
taking testosterone, vaginal atrophy can make the exam painful and more 
triggering.4,5 TM patients also have a nearly 10-fold risk of having a Pap specimen 
return as “inadequate”, making the experience more frustrating and increasing 
the likelihood of loss to follow up.10 
Current guidelines for cervical cancer screening include a Pap test with 
cytology alone every 3 years for patients aged 21-29 years.1 For those aged 30-65 
years, the recommendation is for Pap testing plus hrHPV testing (also known as 
co-testing) every 5 years.1 An alternative for this age group is to continue doing 
the Pap test alone every 3 years. These screening guidelines apply to all women 
with a cervix, regardless of prior HPV vaccination. However, official American 
Congress of Obstetricians and Gynecologists (ACOG) and U.S. Preventative 
Services Task Force (USPSTF) guidelines make no specific mention of the care of 
TM patients.8 This taking place despite lower Pap test frequency in this group 
and confusion regarding cervical cancer risk among patients and providers 
alike.7–9 Compounding the matters above, TM patients frequently experience 
difficulty with insurance coverage if their gender marker changes from female to 
male.4,5 
A less invasive and triggering screening method may be more acceptable to 
TM patients, which would likely increase screening rates in this hard-to-reach 
population. Self-collected samples appear efficacious, although not as good as 
Pap testing, in cisgender women,11 but the research is lacking when it comes to 
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the unique circumstances that TM patients face. This review seeks to explore 
patient perception of self-collection methods and the efficacy of self-collected 
HPV samples among TM patients, especially those taking testosterone. 
METHODS 
A comprehensive literature search using MEDLINE-PubMed, CINAHL, 
and Web of Science was conducted. The following terms were used in the search: 
transmasculine, screening, self, and HPV. For articles that appeared relevant, 
their references were searched for possible additional articles. Included were 
studies conducted on self-identified transmasculine patients, evaluating self-
collected vaginal HPV swabs in comparison to provider-collected cervical 
samples or patient perception of such collection methods. Additionally, studies 
were required to be published in English. Posters, abstracts, presentations, or 
other similar reports that did not list specific study details were excluded, as were 
studies that did not specify the gender identity of subjects. The quality of 
included articles was evaluated using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group guidelines.12 
RESULTS 
The literature search generated 36 articles for review, 17 of which were 
duplicates. The remaining articles were screened using eligibility criteria, yielding 
a total of 3 articles. These articles were 2 observational studies,13,14 and 1 mixed 
methods study15 with a randomized controlled trial portion and an observational 
portion. (See Table 1.)  
Seay et al 
 This was an observational study14 seeking to understand transmasculine 
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individual’s preferences for cervical cancer screening in association with certain 
sociodemographic features and previous healthcare experiences. The study was 
conducted via a community-based participatory research model, in which 
informed community parties collaborate in all aspects of the research. To be 
eligible for the survey, participants needed to self-identify as transgender men 
and they needed to be age 21-65. Subjects were excluded if they reported a 
previous hysterectomy.14 
The authors created a survey that addressed previous experiences with 
preventative healthcare, cervical cancer screening history, sociodemographic 
characteristics, and cervical cancer screening preferences following a description 
of self-sampling procedures. Questions regarding previous healthcare 
experiences were largely based on items from the National Transgender 
Discrimination Survey.16 The survey was completely anonymous and was 
distributed via in-person recruitment at relevant community events in Florida. 
This method proved to be too slow, so the authors switched to email and social 
media recruitment, followed by online delivery of the survey. Ninety-one 
subjects, age 21-63, completed the survey and were included in the analysis.14 
Upon analysis, 90.1% of participants believed transgender men need 
cervical cancer screening, but only 49.5% of participants were adequately 
screened in the past 3 years. In looking at screening preferences, 57.1% preferred 
self-sampling, while only 20.9% preferred Pap testing. The remaining subjects 
expressed no preference (14.3%) or said they would refuse both methods (6.6%). 
The authors conducted a univariate logistic regression to examine the association 
between self-sampling preference and certain sociodemographic factors or 
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previous experiences with healthcare. They found that subjects who said they 
previously avoided preventative care because of cost (OR =3.51, p = .006) or 
discrimination (OR = 3.29, p = .007) were more likely to prefer self-sampling. 
They found no significant association with age, education, race, or employment 
status.14 
The authors concluded that traditional cervical cancer screening 
approaches are less desirable among transgender men and the plausibility of 
alternative methods should be investigated. They did note that their pool of 
participants was not representative of the overall population, and that their study 
did not randomly select participants. They also noted that they only selected 
subjects who identified as transgender men specifically, excluding those that 
identify somewhere else along the transmasculine spectrum.14 
McDowell et al 
 This was an observational study13 in which the authors sought to explore 
cervical cancer screening perceptions and preferences among transmasculine 
individuals. Participants were recruited through social media posts, flyers, and 
outreach at community events in Massachusetts and were eligible if they 
identified as transmasculine, were age 21-64, and had a cervix. Subjects 
completed either an in-person interview (n = 31) or an online survey (n = 32). 
The interview was semi-structured using an interview guide created by experts in 
the fields of cervical cancer, transgender health, and thematic research. The 
questions assessed previous experiences with the healthcare system, perceptions 
of HPV and cervical cancer risk, and attitudes regarding various screening 
methods.  
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The authors utilized thematic analysis to transform qualitative data from 
open-ended interview and survey questions into quantitative, descriptive data. A 
full description of their coding process is described in the original article.13 The 
authors found that 90.3% of in-person interview participants and 68.8% of 
survey participants preferred the self-collected vaginal HPV swab over a 
traditional Pap test. Most subjects (93.5% interview, 90.6% survey) also 
expressed a general preference for a self or provider-collected vaginal HPV swab 
over a traditional Pap test. Participants collectively reported Pap testing to be 
invasive and emotionally uncomfortable, whereas self-sampling promoted 
greater agency and incited less gender dysphoria.13 
Reisner et al 
 This was a mixed methods study,15 with an observational component 
assessing acceptability to patients and a randomized controlled trial portion 
assessing test performance of self-collected HPV samples. The authors recruited 
participants through flyers, referrals, local outreach, and social media, leading to 
150 TM participants. To be eligible, participants had to be age 21-64, identify 
along the masculine spectrum after being assigned female at birth, have a cervix, 
and have been sexually active within the last 3 years. Subjects received $100 as 
compensation. The authors utilized a Community and Provider Task Force, 
comprised of individuals considered experts in transgender healthcare, to ensure 
all aspects of the study were culturally informed.15   
 Participants completed an electronic survey addressing topics such as 
demographics, Pap history, healthcare utilization, and sexual behavior. 
Participants then completed the clinical portion, in which they completed both a 
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self-collected vaginal HPV sample and a provider-collected cervical HPV sample. 
All subjects completed both exams but were randomized as to which sampling 
method they would complete first. This randomization was unblinded. 
Participants were given detailed written instructions and verbal direction for the 
self-collected swab, which they completed in a private room or bathroom stall. 
The provider-collected sample was completed by a physician or nurse 
practitioner. All participants completed an exit questionnaire measuring their 
experience with and perception of the sampling methods. The final 53 
participants completed one additional swab, as the authors identified a gap in the 
research they wished to fill. This was a provider-collected vaginal HPV swab. All 
types of specimens underwent testing for thirteen hrHPV strains using a DNA 
hybridization assay.15 
 The primary outcome variables of the study were concordance (Cohen’s 
kappa statistic) and performance (sensitivity and specificity) of the self-collected 
sample versus the current gold standard (provider-collected cervical sample). 
Concordance (kappa) was categorized as follows: poor (<0), slight (0-.20), fair 
(.21-.40), moderate (.41-.60), substantial (.61-.80), and almost perfect (.81-1.00). 
The authors conducted a sensitivity analysis to assess whether the order of 
collection (randomization component of the study) impacted concordance. They 
also completed a post hoc subgroup analysis to determine whether or not 
testosterone use among participants impacted concordance. Analysis was 
completed on the data from only 131 participants because ten subjects did not 
complete both collections (self and provider) and nine subjects had provider-
collected samples that could not be assayed.15 
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 The authors found that compared to the gold standard, self-collected 
vaginal HPV samples had a sensitivity of 71.4% (95% CI: 0.52-0.91) and a 
specificity of 98.2% (95% CI: 0.96-1.00). In assessing concordance, they found it 
to be substantial (kappa = 0.75; 95% CI: 0.59-0.92; p<.0001). They found no 
statistically significant difference in any of the primary outcome variables when 
adjusting for randomization order. The post hoc analysis revealed no statistically 
significant difference in any of the primary outcomes variables for participants 
currently on testosterone therapy (p = .20) or participants with any prior short or 
long-term testosterone use (p = .60). In comparing the provider-collected vaginal 
specimens to provider-collected cervical specimens (n = 53), sensitivity was 
85.7% (95% CI: .42-1.00) and specificity was 100% (95% CI: .92-1.00). 
Concordance between the provider-collected vaginal specimens and the self-
collected vaginal specimens reached the threshold of ‘almost perfect’ (kappa = 
.84; 95% CI: .61-1.00; p<.0001). The exit interviews showed that 90% of 
participants preferred self-collection over provider-collection.15 
DISCUSSION 
TM adults are under screened, face numerous barriers to care, and 
participate in higher rates of cigarette smoking and risky sexual behavior. All of 
these characteristics increase the risk of persistent hrHPV infection and 
dysplasia.7 This, combined with the fact that TM patients are considerably less 
likely to be up to date on screening,4–6 puts them at increased risk of serious 
morbidity and mortality secondary to cervical cancer. Finding an appealing and 
efficacious alternative is an important step in keeping these patients healthy and 
developing new ways of reaching underserved communities. 
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The 3 included articles13–15 all demonstrate that self-collected vaginal HPV 
swabs are highly acceptable to TM patients. Although much of the data was 
qualitative, making it more difficult to interpret, the interview answers give 
important insight into the care of TM patients. Numerous participants described 
the emotional pain associated with such an invasive exam that often incites 
intense feelings of dysphoria.13 In the Reisner et al study,15 many participants 
noted in their exit interview that self-collection as an alternative would “increase 
healthcare empowerment”, especially in those who may otherwise never 
participate in screening. Importantly, many participants cited the speculum 
specifically as the reason for avoiding Pap testing.13 The self-collection method 
would circumvent this and provide a less triggering form of screening while also 
letting patients remain in control of their bodies. 
The Reisner et al study15 assessing test performance showed that the self-
collected swabs have a reasonable sensitivity and specificity. This study also 
demonstrated that when compared to the gold standard, self-collected vaginal 
HPV swabs have substantial concordance. It is important to note that this study 
included participants who had never completed this test before. They received 
only brief verbal and written instruction, from a provider with whom they did not 
have any rapport. In primary care, with an established patient-provider 
relationship, it is reasonable to believe that the sensitivity, specificity, and 
concordance may be even greater than the study showed.15 Patients could learn 
better technique and have the opportunity to ask meaningful questions to 
improve specimen collection and further build rapport. 
Despite the promising findings, there are numerous limitations in the 
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reviewed studies. Unfortunately, much of the data comes from small, 
observational studies using unvalidated measures to assess attitudes and 
perceptions. Qualitative data, as meaningful as it is, is more difficult to code and 
report in a concise manner without losing the true responses of participants. 
Another major limitation is the fact that each of the participant pools were not 
representative of the general population, as each study employed purposive 
sampling only. Included participants were predominantly white, educated, 
employed, and insured.13–15 It would provide more meaningful insight if the 
studies included those who are most underserved and would likely benefit most 
from self-collection. 
The randomized controlled trial portion of the Reisner et al study15 lacked 
blinding and a true control group. The investigators also added an additional area 
of study (provider-collected vaginal swabs) when two-thirds of the study was 
already complete. Additionally, it is problematic that all data on specificity, 
sensitivity, and concordance came from only one small study. These are areas for 
improvement as research moves forward on this topic. 
CONCLUSION 
If HPV self-swabs are effective, accurate, and acceptable as shown in the 
studies, it appears reasonable to offer it as a primary screening method. Pap 
testing should still be encouraged, and patients should receive education on the 
efficacy of each method, but TM patients should not be pressured into standard 
screening. Pap testing remains superior, but at-home self-collection provides a 
patient-centered and empowerment-based approach to improving the care of TM 
patients. 
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Further study is greatly needed, especially long-term data to assess 
whether self-collected swabs will detect cervical dysplasia and reduce cervical 
cancer. Research among a larger population of TM patients on testosterone is 
also needed to assess the efficacy of self-collected swabs in patients with a very 
high risk of inadequate specimens. Furthermore, research should be conducted to 
determine if this patient-centered option will encourage greater use of the 
healthcare system by TM patients. This approach could serve as a model for other 
necessary screenings in the TM population and beyond. 
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Table I: Quality Assessment of Reviewed Articles 
Outcome 
Number of 
studies 
Study Designs Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Acceptability 
 
3 Observational Seriousa Not Serious Not Serious Not Serious Unlikely None Very Low 
Efficacy 1 RCT Seriousb Not Serious Not Serious Not Serious Likelyc None Low 
a Use of non-validated outcome measures; different outcomes used across studies 
b Lack of blinding in the Reisner et al study 
c Only one small study providing evidence 
 
 
 
 
